Articles
Network meta-analysis of HIF-prolyl hydroxylase inhibitors for anemia in dialysis-dependent and non-dialysis CKD
HIF–prolyl hydroxylase inhibitors (HIF-PHIs) are oral alternatives to erythropoiesis-stimulating agents (ESAs) for anaemia in chronic kidney disease (CKD).
A network meta-analysis comparing six HIF-PHIs (roxadustat, daprodustat, vadadustat, molidustat, enarodustat, desidustat) versus ESAs or placebo across haemoglobin efficacy, iron indices, and adverse events, with prespecified subgroup analyses by dialysis status.
Click here to access the article.